Madrigal Pharmaceuticals Inc (MDGL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.93B
Last updated: Nov 17, 2026 at 11:06 AM ET
Madrigal Pharmaceuticals Inc (MDGL) Financials: Revenue, Profit and Cash Flow
Madrigal Pharmaceuticals reported revenue of $958.40M for the fiscal year ended Dec 31, 2025, up 432.1% from the year before. That year, net income was -$288.28M with a net margin of -30.1%, operating cash flow was -$189.55M and free cash flow was -$190.02M. The quarter ended Sep 30, 2026 had revenue of $431.27M and net income of $55.44M.
Revenue and Margins
The operating margin was -31.3% in the fiscal year ended Dec 2025.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $958.40M | +432.1% | 100.0% | -31.3% | -30.1% |
| Dec 2024 | $180.13M | N/A | 100.0% | -276.4% | -258.6% |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $958.40M | $180.13M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $958.40M | $180.13M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $388.52M | $236.72M | $272.35M | $245.44M | $205.16M | $184.81M | $72.32M | $25.39M | $24.39M | $15.93M |
| Operating income | -$300.10M | -$497.88M | -$380.50M | -$293.57M | -$242.48M | -$206.67M | -$94.97M | -$40.68M | -$32.06M | -$25.22M |
| Net income | -$288.28M | -$465.89M | -$373.63M | -$295.35M | -$241.85M | -$202.24M | -$83.95M | -$32.81M | -$31.15M | -$26.39M |
| EBITDA | -$294.24M | -$495.09M | -$377.56M | -$292.31M | -$241.80M | -$206.10M | -$94.86M | -$40.39M | -$31.64M | -$25.22M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $431.27M | $364.25M | $311.34M | $321.08M | $287.27M | $212.80M | $137.25M | $103.32M | $62.17M | $14.64M | $0 | $770.00K |
| Gross profit | $431.27M | $364.25M | $311.34M | $321.08M | $287.27M | $212.80M | $137.25M | $103.32M | $62.17M | $14.64M | $0 | -$142.00K |
| Operating income | $55.99M | -$56.31M | -$92.72M | -$59.61M | -$113.97M | -$47.20M | -$79.31M | -$67.00M | -$116.30M | -$162.54M | -$152.04M | -$117.18M |
| Net income | $55.44M | -$57.94M | -$94.39M | -$58.58M | -$114.19M | -$42.28M | -$73.24M | -$59.42M | -$106.96M | -$151.97M | -$147.54M | -$112.19M |
Balance Sheet
As of Dec 2025, total debt of $340.90M exceeded cash and equivalents by $142.21M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.26B | $1.04B | $640.55M | $362.57M | $273.33M | $287.00M | $442.06M | $485.43M | $192.31M | $41.21M |
| Current assets | $1.25B | $1.03B | $637.28M | $361.37M | $271.68M | $285.16M | $440.20M | $485.20M | $192.01M | $41.21M |
| Cash and equivalents | $198.69M | $100.02M | $99.92M | $331.55M | $36.27M | $54.00M | $46.70M | $57.38M | $148.63M | $19.14M |
| Total liabilities | $656.90M | $287.86M | $235.21M | $165.18M | $77.22M | $47.02M | $25.49M | $8.44M | $10.05M | $4.80M |
| Short-term debt | $1.02M | $983.00K | $527.00K | $602.00K | $410.00K | $318.00K | $315.00K | N/A | N/A | N/A |
| Long-term debt | $339.88M | $117.57M | $115.48M | $49.29M | $0 | N/A | N/A | N/A | $0 | $0 |
| Shareholder equity | $602.69M | $754.38M | $405.33M | $197.39M | $196.11M | $239.97M | $416.56M | $476.98M | $182.26M | $36.41M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.43B | $1.24B | $1.23B | $1.26B | $1.36B | $1.02B | $996.63M | $1.04B | $1.07B | $1.10B | $1.08B | $640.55M |
| Total liabilities | $807.45M | $720.92M | $683.87M | $656.90M | $736.73M | $319.40M | $285.99M | $287.86M | $296.11M | $242.67M | $231.52M | $235.21M |
| Cash and equivalents | $514.64M | $292.73M | $227.03M | $198.69M | $295.69M | $186.19M | $183.65M | $100.02M | $232.68M | $494.60M | $622.52M | $99.92M |
| Shareholder equity | $626.94M | $523.72M | $543.45M | $602.69M | $625.73M | $695.98M | $710.64M | $754.38M | $777.15M | $857.12M | $850.76M | $405.33M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$189.55M | -$455.57M | -$324.23M | -$224.86M | -$183.92M | -$157.56M | -$41.62M | -$25.51M | -$22.32M | -$17.61M |
| Capital expenditures | $467.00K | $1.46M | $1.48M | $217.00K | $209.00K | $334.00K | $172.00K | $22.00K | $125.00K | $3.00K |
| Free cash flow | -$190.02M | -$457.03M | -$325.71M | -$225.07M | -$184.13M | -$157.90M | -$41.80M | -$25.53M | -$22.44M | -$17.61M |
| Investing cash flow | $32.32M | -$274.39M | -$502.52M | $206.69M | -$5.05M | $159.78M | $30.71M | -$380.08M | -$22.01M | $21.99M |
| Financing cash flow | $255.98M | $735.06M | $595.12M | $313.45M | $171.24M | $5.09M | $235.00K | $314.33M | $173.81M | $14.45M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $120.56M | $23.33M | -$167.44M | -$133.46M | $79.85M | -$47.05M | -$88.89M | -$104.49M | -$66.98M | -$134.94M | -$149.16M | -$79.93M |
| Capital expenditures | $3.93M | $4.25M | $3.85M | $390.00K | $857.00K | $0 | $0 | $195.00K | $779.00K | $131.00K | $357.00K | $1.04M |
| Free cash flow | $116.63M | $19.08M | -$171.28M | -$133.85M | $78.99M | -$47.05M | -$88.89M | -$104.68M | -$67.76M | -$135.08M | -$149.51M | -$80.97M |
Frequently Asked Questions About MDGL
What is Madrigal Pharmaceuticals' annual revenue?
Madrigal Pharmaceuticals reported revenue of $958.40M for the fiscal year ended Dec 31, 2025.
How fast is Madrigal Pharmaceuticals' revenue growing?
Revenue was up 432.1% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Madrigal Pharmaceuticals profitable?
No. Madrigal Pharmaceuticals reported net income of -$288.28M for the fiscal year ended Dec 31, 2025, with a net margin of -30.1%.
How much free cash flow does MDGL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$189.55M minus capital expenditures of $467.00K produced free cash flow of -$190.02M.
How much debt does Madrigal Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $339.88M, short-term debt of $1.02M and cash and equivalents of $198.69M.
MDGL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts